Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with type 2 diabetes. However, the effect on abdominal obesity has not yet been confirmed. The study aimed to systematically evaluate the effect of GLP-1RAs on waist circumference in patients with type 2 diabetes. MEDLINE, EMBASE, the Cochrane library and www.clinicaltrialgov were searched through October 31, 2013. Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks. Weighted mean difference was estimated using random-effect model. Network meta-analysis was performed to supplement direct comparisons. Seventeen trials with 12 treatments were included. Overall, significant reductions on waist circumference following treatment of liraglutide--1.8 mg once daily (-5.24 cm, 95% CI -7.68, -2.93), liraglutide--1.2 mg once daily (-4.73 cm, 95% CI -6.68, -2.65) and exenatide--10 μg twice daily (-1.34 cm, 95 % CI -2.00, -0.75) were detected versus placebo. The reduction effect was more evident when compared with insulin and thiazolidinediones (range -1.71 to -8.03 cm). Compared with exenatide, liraglutide--0.6 mg once daily, taspoglutide, liraglutide--1.2 mg once daily and liraglutide--1.8 mg once daily significantly decreased waist circumference from -3.32 to -6.01 cm. Besides, liraglutide--1.8 mg once daily significantly decreased waist circumference by -1.73 cm (95 % CI -3.04, -0.55) versus sitagliptin, whereas no significant difference following liraglutide--1.2-mg-once-daily treatment was detected compared with liraglutide--1.8 mg once daily and sitagliptin. Reduction was observed with statistical significance for exenatide--10 μg twice daily compared with exenatide--5 μg twice daily (-1.21 cm, 95% CI -2.43, -0.06). Ranking probability analysis indicated liraglutide--1.8 mg once daily and liraglutide--1.2 mg once daily decreased waist circumference most among all 12 treatments with probability of 98.36% and 91.82%, respectively. Some GLP-1RAs, especially liraglutide--1.8 mg once daily and liraglutide--1.2 mg once daily, were associated with a significant reduction in waist circumference.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP-1 RAs decrease waist circumference and blood pressure, modify various elements of the lipid profile, and thus result in reduced CVD risk.
“Aside from their previously mentioned benefits, GLP-1 RAs exert several other favorable effects such as the decrease of waist circumference (WC) [60] and blood pressure (BP) [61], as well as the modification of various elements of the lipid profile, thus resulting in reduced CVD risk [62].”
From Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care (2022) · cites this paper as [60]
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · see citing works
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · see citing works
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033 · see citing works
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766 · see citing works
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,723 · see citing works
Combination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,149 · see citing works
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
Wilson, P. W. F., D’Agostino, R. B., Parise, H., SULLIVAN, L. M., & Meigs, J. B. (2005) · Circulation · doi:10.1161/circulationaha.105.539528 · Cited by 2,061 · see citing works
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600 · see citing works
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works
Song, F., Altman, D. G., Glenny, A., & Deeks, J. J. (2003) · BMJ · doi:10.1136/bmj.326.7387.472 · Cited by 944 · see citing works
Automating network meta‐analysis
van Valkenhoef, G., Lu, G., de Brock, B., Hillege, H. L., Ades, A. E., & Welton, N. J. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1054 · Cited by 793 · see citing works
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · see citing works
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · see citing works
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · see citing works
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · see citing works
Matsuzawa, Y., Funahashi, T., & Nakamura, T. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.7922 · Cited by 452 · see citing works
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430 · see citing works
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · see citing works
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · see citing works
Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Garber, A. J., Thomsen, A. B., Hartvig, H. B., Davies, M. J., et al. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02656.x · Cited by 253 · see citing works
Harder, H., Nielsen, L., Thi, T. D. T., & Astrup, A. V. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1915 · Cited by 232 · see citing works
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · see citing works
Bayesian Measures of Model Complexity and Fit
Spiegelhalter, D. J., Best, N. G., Carlin, B. P., & Van Der Linde, A. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00353 · Cited by 151 · see citing works
Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01154.x · Cited by 144 · see citing works
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130 · see citing works
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127 · see citing works
GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104 · see citing works
DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104 · see citing works
Diamant, M., Gaal, L. V., Stranks, S. N., Guerci, B., MacConell, L., Haber, H. E., Scism-Bacon, J. L., & TRAUTMANN, M. E. (2012) · Diabetes Care · doi:10.2337/dc11-1233 · Cited by 95 · see citing works
Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
Davies, M., Heller, S., Sreenan, S., Sapin, H., Adetunji, O., Tahbaz, A., & Vora, J. (2013) · Diabetes Care · doi:10.2337/dc12-1333 · Cited by 83 · see citing works
GLP ‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
Lorber, D. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12000 · Cited by 77 · see citing works
Forst, T., Michelson, G., Ratter, F., Weber, M. M., Anders, S., Mitry, M., Wilhelm, B., & Pfützner, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03589.x · Cited by 75 · see citing works
Liutkus, J., Guzmán, J. R., Norwood, P. C., Pop, L., Northrup, J., Cao, D., & TRAUTMANN, M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01251.x · Cited by 74 · see citing works
Buysschaert, M., Preumont, V., Oriot, P. R., Paris, I., Ponchon, M., Scarnière, D., & Selvais, P. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.009 · Cited by 68 · see citing works
Li, C., Li, J., Zhang, Q.-M., Lv, L., Chen, R., Lv, C.-F., Yu, P., & Yu, D. M. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-142 · Cited by 64 · see citing works
Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., & Campbell, R. K. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m134 · Cited by 63 · see citing works
Kadowaki, T., Namba, M., Imaoka, T., Yamamura, A., Goto, W., Boardman, M. K., & Sowa, H. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00084.x · Cited by 50 · see citing works
Insulin Glargine: a review 8 years after its introduction
Goykhman, S., Drincic, A., Desmangles, J., & Rendell, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902775677 · Cited by 49 · see citing works
Wajcberg, E., & Tavaria, A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802611832 · Cited by 41 · see citing works
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hansen, K. B., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02086.x · Cited by 35 · see citing works
Raz, I., Fonseca, V. A., Kipnes, M. S., Durrwell, L., Hoekstra, J., Boldrin, M. N., & Balena, R. (2012) · Diabetes Care · doi:10.2337/dc11-1942 · Cited by 34 · see citing works
Hollander, P. A., Lasko, B., Barnett, A. H., Bengus, M., Kanitra, L., Pi‐Sunyer, F. X., & Balena, R. (2013) · Obesity · doi:10.1002/oby.20042 · Cited by 30 · see citing works
Henry, R. R., Mudaliar, S. R. D., Kanitra, L., Woloschak, M., Balena, R., & for the T-Emerge 3 Study Group (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3253 · Cited by 30 · see citing works
Derosa, G., Franzetti, I., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1301 · Cited by 29 · see citing works
Bhushan, R., Elkind-Hirsch, K. E., Bhushan, M., Butler, W. J., Duncan, K., & Marrioneaux, O. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0090 · Cited by 28 · see citing works
Yanai, H. (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr975w · Cited by 23 · see citing works
Ezenwaka, C. E., Okoye, O., Esonwune, C., Onuoha, P. C., Dioka, C. E., Osuji, C. U., Oguejiofor, C. O., & Meludu, S. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2013.0139 · Cited by 21 · see citing works
Nagao, H., Kashine, S., Nishizawa, H., Okada, T., Kimura, T., Hirata, A., Fukuda, S., Kozawa, J., Maeda, N., Kitamura, T., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-88 · Cited by 21 · see citing works
Pratley, R. E., Urosevic, D., Boldrin, M. N., Balena, R., & for the T‐emerge 6 Study Group (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12009 · Cited by 20 · see citing works
Behavioral aspects of weight loss in type 2 diabetes
Wing, R. R., & Marquez, B. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0023-0 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398 · see citing works
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Scheen, A. J., Esser, N., & Paquot, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.003 · Cited by 155 · see citing works
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140 · see citing works
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135 · see citing works
Vuksan, V., Jenkins, A. L., Brissette, C., Choleva, L., Jovanovski, E., Gibbs, A. L., Bazinet, R. P., Au-Yeung, F., Zurbau, A., Ho, H. V. T., et al. (2017) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.11.124 · Cited by 125 · see citing works
Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.063 · Cited by 118 · see citing works
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
Zaccardi, F., Htike, Z. Z., Webb, D. R., Khunti, K., & Davies, M. J. (2015) · Annals of Internal Medicine · doi:10.7326/m15-1432 · Cited by 91 · see citing works
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87 · see citing works
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60 · see citing works
Kalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 58 · see citing works
Ling, J., Peng, C., Ge, L., Ding-hua, Z., Shi, A., Tian, J., Chen, Y., Li, X., Zhang, J., & Yang, K. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1222-z · Cited by 55 · see citing works
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 56 · see citing works
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 50 · see citing works
Deol, H., Lekkakou, L., Viswanath, A., & Pappachan, J. M. (2016) · Endocrine · doi:10.1007/s12020-016-1125-0 · Cited by 41 · see citing works
Liu, L., Shi, H., Shi, Y., Wang, A., Guo, N., Tao, H., & Nahata, M. C. (2024) · Pharmaceuticals · doi:10.3390/ph17070828 · Cited by 43 · see citing works
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Dieter, B. P., Alicic, R. Z., & Tuttle, K. R. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00211.2018 · Cited by 38 · see citing works
He, W., Zhang, Y., Huang, G., Tian, Y., Sun, Q., & Liu, X. (2023) · LUTS Lower Urinary Tract Symptoms · doi:10.1111/luts.12475 · Cited by 26 · see citing works
Self-citationMechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 25 · see citing works
Cardiovascular effects of anti-diabetes drugs
Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 23 · see citing works
Dahlqvist, S., Ahlén, E., Filipsson, K., Gustafsson, T. P., Hirsch, I. B., Tuomilehto, J., Imberg, H., Åhrén, B., Attvall, S., & Lind, M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000464 · Cited by 24 · see citing works
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 23 · see citing works
Self-citationRondinelli, M., Rossi, A., Gandolfi, A., Saponaro, F., Bucciarelli, L. G., Adda, G., Molinari, C., Montefusco, L. B., Specchia, C., Rossi, M. C., et al. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.001 · Cited by 19 · see citing works
Glucagon-like Peptide-1 Receptor Agonists
Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16 · see citing works
Ahmadi, S. S., Filipsson, K., Dimenäs, H., Isaksson, S. S., Imberg, H., Sjöberg, S., Åhrén, B., Dahlqvist, S., Gustafsson, T. P., Tuomilehto, J., et al. (2018) · Obesity Science & Practice · doi:10.1002/osp4.324 · Cited by 13 · see citing works
Wen, Z., Sun, W., Wang, H., Chang, R., Wang, J., Song, C., Zhang, S., Ni, Q., & An, X. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.111999 · Cited by 13 · see citing works
Fu, X., Wu, H., Li, J., et al. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00223 · Cited by 13 · see citing works
Widiarti, W., Sukmajaya, A. C., Nugraha, D., & Alkaff, F. F. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.005 · Cited by 13 · see citing works
Zhao, Y., Huang, G., He, W., Sun, Q., Zhao, X., Li, D., Wang, H., Cui, W., & Liu, X. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27729 · Cited by 11 · see citing works
Nowrouzi‐Sohrabi, P., Soroush, N., Tabrizi, R., Shabani-Borujeni, M., Rezaei, S., Jafari, F. M., Hosseini‐Bensenjan, M., Stricker, B. H. C., van Hoek, M., & Ahmadizar, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618208 · Cited by 11 · see citing works
He, X., Guan, H., Liang, W., Huang, Z., Xu, L., Zhang, P., Xu, F. L., & Li, Y. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0024-2 · Cited by 8 · see citing works
Esteghamati, A., Zamanzadeh, M., Malek, M., Khaledi, M., MONAVVARI, A., Najafi, L., Banazadeh, Z., Malboosbaf, R., Aghili, R., Mahdikhah, S., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01462-w · Cited by 8 · see citing works
Åhrén, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30002-7 · Cited by 7 · see citing works
Damen, J. A., Idema, D. L., Vernooij, R. W. M., Veld, L. F. H. I. ’., Kusters, M. P. T., Lokerse, M. E., de Kanter, E., Spijker, R., van der Braak, K., Jenniskens, K., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-24-03764 · Cited by 7 · see citing works
Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist
Kim, H. J. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.2.126 · Cited by 6 · see citing works
Emerging therapeutic frontiers in hypertension management
Pena, D.-L., Aurelian, J., Grigore, M., Hodorogea, A. S., Weiss, E., Bădilă, E., Ilieșiu, A.-M., & Balahura, A.-M. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1550181 · Cited by 3 · see citing works
Xu, L., Yu, S. Q., Gao, L., Huang, Y., Wu, S., Yang, J., Sun, Y. X., Yang, Z., Chai, S. B., Zhang, Y., et al. (2020) · PubMed · doi:10.3967/bes2020.005 · Cited by 3 · see citing works
Self-citationLópez, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2023) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 2 · see citing works
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 3 · see citing works
Pi, Y., Du, T. T., & Zhao, P. (2022) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.976 · Cited by 1 · see citing works
Inflammatory Mechanisms in Diabetic Kidney Disease
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_32 · Cited by 1 · see citing works
Avcı, D., & Çetinkaya, A. (2019) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2019.72001
Murín, J., Bulas, J., & Wawruch, M. (2020) · Klinická farmakologie a farmacie · doi:10.36290/far.2020.028
Giglio, R. V., Gambino, C. M., Patti, A. M., Scazzone, C., Maggio, V., MURATORE, E., Agnello, L., RIZZO, M., & Ciaccio, M. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00059-7
Popoviciu, M. S., Reurean‐Pintilei, D., Salmen, T., Rus, M., Ferician, A. C., Sava, C. N., Ardelean, A. I., Moroianu, L.-A., & Stoian, A. P. (2025) · Biomedicines · doi:10.3390/biomedicines13092174 · Cited by 1 · see citing works
- Authors
- Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S.
- Affiliations
- Shihezi University (CN)
- Peking University (CN)
- Fifth Tianjin Central Hospital (CN)
- Corresponding author
- Zhan, Siyan
- Venue
- Endocrine
- Published
- 2014-08-13
- Volume
- 48
- Issue
- 3
- Pages
- 794-803
- ISSN
- 0969-711X (ISSN-L)
- 1355-008X
- 1559-0100
- OpenAlex
- W2022207575
- Semantic Scholar
- c23e0c69c8f8b671cdcf6d0f6a7a3f1c60af7ae0
- Cited by
- 44
- References
- 51
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 1 · 2016: 6 · 2015: 4
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Endocrine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, waist circumference, abdominal obesity, type 2 diabetes, liraglutide, exenatide, sitagliptin, insulin, thiazolidinediones, weight loss, antidiabetic drugs, comparative effectiveness, placebo comparison, dose comparison, treatment duration comparison
- MeSH terms
- Liraglutide, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Peptides, Venoms, Treatment Outcome, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
